WKYMVm

WKYMVm is a selective formylpeptide receptor 2 (FPR2) agonist. WKYMVm has a powerful anti-inflammatory effect that can reduce lung injury and spinal cord injury. WKYMVm ameliorates obesity by regulating lipid metabolism and leptin signaling. WKYMVm is involved in the regulation of immune cells by activating FPRs. WKYMVm can promote the chemotactic migration of immune cells and inhibit the apoptosis of phagocytes. In addition, WKYMVm may play a favorable or unfavorable role in tumors, depending on the type of tumor^{[1][2][3][4][5][6][7]}. IC50 & Target:FPR1, FPRL1^[1], FPRL2^[2] In Vitro: WKYMVm (0-5 μmol/L; 2 h) inhibits the production of inflammatory cytokines (TNF-α, IL-6 and IL-1β) in LPS (HY-D1056) treated microglia ^[3].
WKYMVm (1-100 µM; 0-24 h) can increase FPR2 mRNA level and ERK phosphorylation level in HUVECs cells, promote HUVECs tube formation and cell proliferation^[4]. In Vivo: WKYMVm (4 mg/kg; Intraperitoneal injection; 3 times; 24 h interval) has a protective effect in rat spinal cord injury model^[3].
WKYMVm (2.5 mg/kg; Intraperitoneal injection; 4 days) can alleviate hyperoxy-induced lung injury in neonatal mice^[4].
WKYMVm (8 mg/kg; Subcutaneous injection; Once every two days; 2-5 weeks) improves obesity in high-fat fed mouse models^[5].